

TRACER (S1415CD) NEWSLETTER

January 2017

STUDY UPDATES

We have officially recruited and randomized **ALL** components for the TrACER study. Welcome to our new components!

UPCOMING EVENTS

We have scheduled a series of webinars in February to introduce new sites to the study, update current sites on study progress, and give everyone a chance to provide feedback and ask questions of the study chairs and support staff. **If you have any specific questions or issues for the webinar agendas, please send them to TrACER@fredhutch.org by January 30th, 2017.**

- ◆ **Cohort/Usual Care Arms:**
2/6/17 10-11AM PST (12-1PM CT, 1-2PM EST),
2/7/17 9-10AM PST (11AM-12PM CT, 12-1PM EST)
- ◆ **Intervention Arms:**
2/7/17 12-1PM PST (2-3PM CT, 3-4PM EST),
2/8/17 11AM-12PM PST (1-2PM CT, 2-3PM EST)

We have a 2 hour meeting scheduled during the SWOG spring meeting in San Francisco. Please mark your calendars to attend **Thursday, April 27th from 10:00 am -12:00 pm.**

TrACER: A Pragmatic Trial Assessing CSF Prescribing Effectiveness and Risk

This pragmatic trial is designed to test an intervention to increase compliance with guidelines, and generate evidence to assess effectiveness of Primary Prophylactic CSF (PP-CSF) on reducing rates of FN for patients receiving intermediate-risk chemotherapy regimens. TrACER is the first trial of its kind, and is sponsored by SWOG, a part of the National Clinical Trials Network. The trial is led by Dr. Scott Ramsey at HICOR, and funded in part by PCORI.

CONGRATULATIONS

Saint Luke's Mountain States Tumor Inst, Boise, ID for our FIRST Usual Care component to begin registration!

Cancer Care Specialists of Central Illionois, Decatur, for completing the order change process in their system!

Our top 3 accruing components as of January 9, 2017

Institution	NCI Code	Total Registrations
Mercy Hospital Springfield	MO043	17
Illinois Care Care- Peoria	IL101	11
Greenville Memorial Hospital	SC045	10

Thank you all for your participation in TrACER!

FAQS OF THE MONTH - January, 2017

1. Is it acceptable to register a patient for TrACER if the patient is going to receive radiation therapy at the same time as their approved TrACER regimen?

No. Regimens with concurrent radiation will not be addressed by TrACER as radiation is a contraindication for primary prophylactic growth factors. See protocol section 18.1.

2. If a patient changes his/her chemotherapy regimen due to progression or another reason, does the patient continue on this protocol?

Yes. All patients will be followed for 12 months from registration date, regardless of any changes to the patient's initial chemotherapy regimen. See protocol section 7.6.

HELPFUL INFORMATION/REMINDERS

✦ **Best practices for entering patient completed forms into Rave**

Each question on the patient completed forms for S1415CD within Rave include an option of "Not answered by patient". If a patient does not respond to a question, for any reason, "Not answered by patient" should be selected. Please review each patient completed form in Rave to verify that the patient's response or "Not answered by patient" is selected for each question. NOTE: On most of the questionnaires, "Not answered by patient" is chosen from a drop-down box. On the Follow-Up Patient Survey, questions 15, 19 and 24, "Not Answered By Patient" is one of the visible multiple choice options.

- ✦ If you have any sub-components that will be participating in the trial with you (share the same EHR - Electronic Health Record), please be sure to send us their CTEP IDs. If we do not have their CTEP IDs, they will not be included in the list to access the study database.
- ✦ Sites must obtain local IRB approval for this study; CIRB is not available. Let the TrACER team know if you run into any problems with this process.

Intervention sites:

- ✦ **Do not begin accruing patients until the HICOR team has approved your system changes.**
- ✦ Once you have an implementation plan in place, please contact TrACER@fredhutch.org to receive the Implementation questionnaire. **The completed questionnaire must be reviewed by HICOR prior to making changes in your system.**
- ✦ Contact the TrACER team if you need any consultant assistance in your order change process. We currently have consultants on call for EPIC, Mosaiq, and Cerner. We are happy to source consultants for other systems upon request.

New Intervention sites:

- ✦ Please complete the clinic characterization survey at <https://www.surveymonkey.com/r/V9R7XVC>.
- ✦ Once your survey has been completed, please contact TrACER@fredhutch.org to set up a phone call with the HICOR study team.

Contact Us

Site Requirements, including regimen questions: HICOR, TrACER@fredhutch.org; phone: 206-667-7624
Patient eligibility, study procedures, and data submission: cancercontrolquestion@crab.org; phone: 206-652-2267